Back to results
US 2012/0258998 A1Published application
Fusion genes in gastrointestinal cancer
OwnerPatrick Tan, Jiong Taoinventors
Life of this patent
Estimating the term…
Abstract
A method of treating or preventing a gastrointestinal cancer by inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or by inhibiting the activity of a fusion protein expressed by the CD44-SLC1A2 fusion gene or the functional variant thereof.
Claims30
A method of treating or preventing a gastrointestinal cancer, comprising:
- inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or
- inhibiting the activity of a fusion protein encoded by the CD44-SLC1A2 fusion gene or the functional variant thereof.
A method of sensitizing cells to a cancer treatment in a patient suffering from a gastrointestinal cancer, comprising:
- inhibiting expression of a SLC1A2 gene, or a CD44-SLC1A2 fusion gene, or a functional variant of these genes;
- or
- inhibiting the activity of a fusion protein encoded by the CD44-SLC1A2 fusion gene or its functional variant, or the protein encoded by the SLC1A2 gene or its functional variant.
A method of reducing intracellular glutamate level of a cell, comprising:
- inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or
- inhibiting the activity of a fusion protein encoded by the CD44-SLC1A2 fusion gene or the functional variant thereof.
-50. (canceled)
Dependencies are inferred from the claim text.